CorAlert

Company Overview

Snapshot

Founded in December 2012 by Amir Marmor and Alon Marmor, CorAlert operated with 1-10 employees. The company ceased operations in March 2023.

Business overview

CorAlert developed a noninvasive device for the early detection and real-time monitoring of heart failure. Its core technology estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from brachial artery measurements and heartbeat sounds. The device provides a comprehensive hemodynamic profile, including the rate of pressure increase in the aorta (dP/dt) and an index correlated to systemic vascular resistance (SVR). CorAlert served the healthcare industry, specifically targeting providers within the digital healthcare and medical devices sectors, focusing on patient remote monitoring and medical monitors.

Company Intelligence Q&A

What is CorAlert's operational status?

CorAlert ceased to operate in March 2023.

When was CorAlert founded and by whom?

CorAlert was founded in December 2012 by Amir Marmor and Alon Marmor.

What is CorAlert's primary technological focus?

CorAlert developed a noninvasive device for the early detection and real-time monitoring of heart failure, utilizing central aortic pressure and heartbeat sound analysis to estimate left ventricular end-diastolic pressure (LVEDP).

What clinical validation has CorAlert conducted?

CorAlert's solution was validated in 10 patients during a clinical trial at Ziv Medical Center in Israel using its alpha model. The company also commenced a clinical trial in Israel with its beta model.

What was the strategic focus of CorAlert's technology?

CorAlert's technology aimed to provide a comprehensive hemodynamic picture to physicians, enabling accurate determination of a patient's precise condition and type of dysfunction in heart failure management.